What is the recommended management plan for eczema, including moisturization, topical corticosteroids, and criteria for escalation to phototherapy or systemic therapy?

Management of Eczema (Atopic Dermatitis)

Start all patients with consistent moisturization and topical corticosteroids (TCS) as first-line therapy, escalating to phototherapy or systemic agents only after optimizing topical treatment and ruling out alternative diagnoses. 1

Foundation: Basic Management

Moisturization

• Apply emollients liberally and frequently throughout the day
• Use soap substitutes and bath oils consistently
• Moisturizers improve skin barrier function and are essential for flare prevention 2, 3

Trigger Avoidance

• Identify and avoid specific irritants and trigger factors
• Not all patients with atopic dermatitis have allergies 3
• Address trigger reduction through therapeutic patient education 2

First-Line: Topical Anti-Inflammatory Therapy

Topical Corticosteroids (TCS)

TCS remain the cornerstone of treatment with strong evidence for efficacy and safety 2, 4

Potency selection by body site:

• Potent TCS for trunk and extremities (ranked most effective alongside tacrolimus 0.1% and ruxolitinib 1.5%) 4
• Moderate TCS for less severe areas
• Mild TCS for face, neck, and intertriginous areas where potent TCS are potentially harmful 5

Application strategy:

• Use reactive (as-needed for inflamed areas) OR proactive (maintenance application to recurrently inflamed sites) 1
• Short-term use (median 3 weeks) shows no evidence of skin thinning 4
• Address steroid phobia directly—side effects are infrequent with appropriate use 2

Alternative Topical Agents

For sensitive sites (face, genitals) or steroid-intolerant patients:

• Tacrolimus 0.1% (ranked equally effective as potent TCS; OR 5.06 for treatment success) 4
• Pimecrolimus 1% (less effective but useful for facial eczema)
• Roflumilast cream 0.15% (PDE-4 inhibitor, FDA-approved 2024 for mild-moderate AD ages ≥6 years; moderate improvement in disease severity with favorable safety profile) 1
• Ruxolitinib 1.5% (JAK inhibitor; ranked among most effective with OR 9.34 for treatment success) 4

Common pitfall: TCI (tacrolimus, pimecrolimus) cause application-site reactions more frequently than TCS (OR 2.2 for tacrolimus 0.1%), which may affect adherence 4

Criteria for Escalation

Before advancing to phototherapy or systemic therapy, complete this systematic assessment: 5

1. Verify Inadequate Control

• Severe signs/symptoms persist despite optimized topical therapy
• Significant impact on quality of life (even if extent is small—face, hands, genitals)
• Do not rely solely on severity scores—use holistic assessment including QoL impact 5

2. Rule Out Alternative/Concomitant Diagnoses

• Contact dermatitis
• Cutaneous lymphoma
• Secondary infection requiring treatment 1, 5

3. Optimize Current Management

• Confirm adequate patient/caregiver education on disease and medication use 5
• Verify adherence to moisturization and topical therapy
• Treat any coexistent infection 5

4. Consider Adjunctive Measures

• Dilute bleach baths (may help during flares, though evidence is inconsistent) 2
• Wet-wrap therapy (adds complexity but may be useful in selected patients) 2
• Antihistamines are no longer routinely recommended 2

Second-Line: Phototherapy

Consider phototherapy when topical therapy fails but before systemic agents 5, 6

• Narrowband UVB (NB-UVB) is preferred first-line phototherapy (80.9% of European dermatologists) 7
• NB-UVB may improve physician-rated signs, patient symptoms, and IGA after 12 weeks versus placebo 6
• Typical duration: 2-3 times weekly for several weeks
• Limitation: Primarily for adults; less practical for young children

Third-Line: Systemic Therapy

Escalate to systemic treatment when:

• Moderate-to-severe AD unresponsive to optimized topical therapy
• Phototherapy is not viable, ineffective, or poorly tolerated 5

Systemic Options (in order of common first-line use):

Traditional immunosuppressants:

1. Cyclosporine (54.1% use as first-line systemic) 7
2. Methotrexate (30.7% first-line use) 7
3. Azathioprine and mycophenolate (less commonly used due to lack of provider experience) 7

Biologic therapy (FDA-approved for moderate-to-severe AD):

• Dupilumab (IL-13/IL-4 inhibitor)
• Lebrikizumab (IL-13 inhibitor, FDA-approved 2024 for ages ≥12 years) 1
• Nemolizumab (newer option) 8
• Tralokinumab (IL-13 inhibitor) 8

JAK inhibitors:

• Baricitinib, upadacitinib, abrocitinib (oral) 8

Avoid:

• Systemic corticosteroids should not be routine due to rebound flares and long-term adverse effects, despite 32.6% of providers using them first-line 7

Decision-Making for Systemic Therapy

Base the decision on:

• Disease severity AND quality of life impact (not severity alone) 5
• Individual's general health status
• Psychological needs
• Personal attitudes toward systemic therapies 5
• Known risks of traditional immunosuppressants versus newer targeted agents

Common pitfall: Providers often rely on personal experience rather than evidence-based guidelines when selecting systemic therapy 7—prioritize agents with strongest evidence for your patient's specific situation.

Maintenance Strategy

Once control is achieved:

• Continue reactive (as-needed) application to inflamed areas, OR
• Use proactive maintenance therapy to recurrently inflamed sites 1
• Engage in shared decision-making about long-term treatment
• Assess patient satisfaction and ability to adhere 1

For longer-term TCS use (6-60 months): Monitor for skin thinning, which increases with prolonged mild-to-potent TCS versus TCI 4